Salts of trimebutine and N-desmethyl trimebutine

Details Salts of trimebutine and N-desmethyl trimebutine Salts of trimebutine and N-desmethyl trimebutine

2007-06-06

2010-02-23

Keys, Rosalynd (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S018700, C562S560000

Reexamination Certificate

active

07666907

ABSTRACT:
Unique salts of trimebutine and N-monodesmethyl trimebutine, and their corresponding stereoisomers, having improved analgesic properties useful in the treatment of visceral pain are provided. The salts of the present invention are particularly useful in the treatment of conditions characterized by abdominal pain, such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), diabetic gastroparesis, and dyspepsia.

REFERENCES:
patent: 4301163 (1981-11-01), Torossian et al.
patent: 4412992 (1983-11-01), Chan
patent: 4440763 (1984-04-01), Lover
patent: 4751221 (1988-06-01), Watanabe et al.
patent: 5013727 (1991-05-01), Halskov
patent: 5245080 (1993-09-01), Aubard et al.
patent: 5541170 (1996-07-01), Rhodes et al.
patent: 5811547 (1998-09-01), Nakamichi et al.
patent: 6197341 (2001-03-01), Friess et al.
patent: 6353024 (2002-03-01), Grouhel et al.
patent: 6458776 (2002-10-01), Ekwuribe et al.
patent: 6602915 (2003-08-01), Uhrich et al.
patent: 6986901 (2006-01-01), Meisel et al.
patent: 7041704 (2006-05-01), Burgard et al.
patent: 2002/0165276 (2002-11-01), Brunelle et al.
patent: 2003/0119903 (2003-06-01), Grouhel et al.
patent: 2204747 (1997-03-01), None
patent: 1645288 (2006-04-01), None
patent: WO 98/48826 (1998-11-01), None
patent: WO 2004/006902 (2004-01-01), None
Berge, S.M. et al., Pharmaceutical Salts, 1977, Journal of Pharmaceutical Sciences, vol. 66, No. 1, pp. 1-19.
Pellicciari, et al., Brush-Border-Enzyme-Mediated Intestine-Specific Drug Delivery. Amino acid Prodrugs of 5-Aminosalicylic acid, J. Med. Chem. 1993, vol. 36, pp. 4201-4207.
Dzierzewicz, et al., Susceptibility of Desulfovibrio desulfuricans intestinal strains to sulfasalazine and its biotransformation products, Med. Sci. Monit., 2004, vol. 10, No. 6, BR185-190.
Edmond, et al., The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing bacteria and amino acid-fermenting bacteria, Inflammatory Bowel Diseases, 2003, vol. 9, No. 1, pp. 10-17.
Fiorucci, et al., Inhibition of Hydrogen Sulfide Generation Contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs, Gastroenterology, Oct. 2005, vol. 129, No. 4, pp. 1210-1224.
Distrutti, et al., Evidence that Hydrogen Sulfide exerts Antinociceptive Effects in the Gastrointestinal Tract by Activating KATP Channels, J. Pharmacology & Exp. Ther., Web Release on Sep. 25, 2005, vol. 316, No. 1, pp. 325-335.
Sidhu, et al., L-Cystein and Sodium Hydrogensulfide Inhibit Spontaneous Contractibility in Isolated Pregnant Rat Uterine Strips In Vivo, Pharmacology & Toxicology, 2001, vol. 88, pp. 198-203.
Zhao, et al., The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener, EMBO Journal, 2001, vol. 20, No. 21, pp. 6008-6016.
Zhao, et al., H2S-induced vasorelaxation and underlying cellular and molecular mechanisms, A. J. Physiol. Heart Circ. Physiol., 2002, vol. 283: H474-480.
Teague, et al., “The Smooth Muscle Relaxant Effect of Hydrogen Sulfide In Vitro: Evidence for a Physiological Role to Control Intestinal Contractility”, Br. J. Pharmacol, vol. 137, pp. 139-145.
Abe, et al., “The possible role of hydrogen sulfide as an endogenous neuromodulator”, The Journal of Neuroscience, 1996, vol. 16, No. 3, pp. 1066-1071.
Carceller, et al., “Novel Azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity”, J. Med. Chem., 2001, Vol. 44, No. 18, pp. 3001-3013.
Roman, Francois, J. et al., Pharmacological Properties of Trimebutine and N-Monodesmethyltrimebutine, The Journal of Pharmacology and Experimental Therapeutics, vol. 289, No. 3., 1391-1396.
Fornai, Matteo, et al.,Differential role of cycooxygenase 1 and 2 isoforms in the modulation of colonic neuromuscular function in experimental inflammation, American Society for Pharmacology and Experimental Therapeutics, Feb. 1, 2006, JPET#98350.
Salvemini, D. et al., Endogenous Nitric Oxide Enhances Prostaglandin Production in a Model of Renal Inflammation, J. Clin. Invest vol. 93, May 1994, 1940-1947.
Uchiyama, Masanori et al., Effects of Trimebutine on Intestinal Motility after Massive Small Bowel Resection, J. Smooth Muscle Res. (2000) 36, 117-126.
Ghidini et al (1986) Single drug treatment for irritable colon: Rociverine versus trimebutine maleate. Curr Ther Res 39: 541-548.
Gauthier et al (1994) Nitric oxide attenuates leukocyte-endothelial interaction via P-selectin in splanchnic ischemiareperfusion. Am J Physiol 267: G562-G568.
Walford and Loscalzo (2003) Nitric oxide in vascular biology. J Thromb Haemost 1:2112-2118.
Kayser, V. et al., Antinociceptive effect of (S)-N-desmethyl trimebutine against a mechanical stimulus in a rat model of peripheral neuropathy, Life Sci. 2000:66(5):433-9.

Affiliated with

Also associated with

Rating

Salts of trimebutine and N-desmethyl trimebutine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Salts of trimebutine and N-desmethyl trimebutine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Salts of trimebutine and N-desmethyl trimebutine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4171901